Arecor AGM statement

Arecor Therapeutics plc

("Arecor" or the "Group")

AGM STATEMENT

Building on strong foundations to deliver a transformational year

Cambridge, UK, 23 May 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, provides the following update ahead of its Annual General Meeting, held today at 1.00 pm at the offices of Covington & Burling LLP, 22 Bishopsgate, London EC2N 4BQ.

At the meeting, Andrew Richards, Non-Executive Chair, will make the following statement:

"2021 was a truly transformational year for Arecor and the Company has continued to make huge strides to continue this trajectory of growth.  During the year, our pipeline of proprietary and partnered products received validation through both exceptional clinical data and partnership progress. It is our vision to create a sustainable biopharmaceutical company, by rejuvenating existing therapeutic products to make them better, safer and more convenient to use. 

Our two lead clinical stage programmes are focused on improving the lives of those living with diabetes.  The impact that the growing global number of diabetes patients is having on our resources, health sector and lives cannot be underestimated.  The Phase I clinical trial data for both our lead product, AT247, an ultra-rapid insulin and for our second product AT278, a concentrated rapid insulin targeting patients who require higher volumes of insulin, excelled our expectations.  We believe that our products will provide that key to unlock the future treatment landscape for diabetes.

With our partnered portfolio continuing to attractive high calibre pharmaceutical companies and strong support from our shareholders following our successful IPO on the London Stock Exchange last year, we believe that Arecor is well positioned to both deliver on existing programmes and attract new and exciting opportunities in the coming year to create long-term shareholder value."

Further information about the AGM can be found in the investor centre section of our website https://arecor.com/investor-centre/shareholder-information/. To register for the webinar, click here.

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com